CA3066979A1 - Chemical compounds as h-pgds inhibitors - Google Patents

Chemical compounds as h-pgds inhibitors Download PDF

Info

Publication number
CA3066979A1
CA3066979A1 CA3066979A CA3066979A CA3066979A1 CA 3066979 A1 CA3066979 A1 CA 3066979A1 CA 3066979 A CA3066979 A CA 3066979A CA 3066979 A CA3066979 A CA 3066979A CA 3066979 A1 CA3066979 A1 CA 3066979A1
Authority
CA
Canada
Prior art keywords
naphthyridine
carboxamide
substituted
fluoro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3066979A
Other languages
English (en)
French (fr)
Inventor
Dave Norman Deaton
Barry George Shearer
Mark Andrew Youngman
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CA3066979A1 publication Critical patent/CA3066979A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3066979A 2017-06-13 2018-06-11 Chemical compounds as h-pgds inhibitors Abandoned CA3066979A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762518779P 2017-06-13 2017-06-13
US62/518,779 2017-06-13
US201762522869P 2017-06-21 2017-06-21
US62/522,869 2017-06-21
PCT/IB2018/054206 WO2018229629A1 (en) 2017-06-13 2018-06-11 Chemical compounds as h-pgds inhibitors

Publications (1)

Publication Number Publication Date
CA3066979A1 true CA3066979A1 (en) 2018-12-20

Family

ID=62948277

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066979A Abandoned CA3066979A1 (en) 2017-06-13 2018-06-11 Chemical compounds as h-pgds inhibitors

Country Status (9)

Country Link
US (1) US11149035B2 (https=)
EP (1) EP3638672A1 (https=)
JP (1) JP2020523367A (https=)
CN (1) CN110753692A (https=)
BR (1) BR112019026452A2 (https=)
CA (1) CA3066979A1 (https=)
TW (1) TW201908311A (https=)
UY (1) UY37764A (https=)
WO (1) WO2018229629A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085293A1 (en) * 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds
JP2022506850A (ja) * 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
CN109651241B (zh) * 2018-12-27 2021-02-09 上海毕得医药科技股份有限公司 一种4-溴-6-氯烟醛的合成方法
WO2021256569A1 (ja) 2020-06-19 2021-12-23 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害する縮環化合物
CN112430632B (zh) * 2020-11-18 2022-09-13 上海合全药物研发有限公司 2-((反式)-4-氨基环己烷基)异丙醇的制备方法
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
CA3240926A1 (en) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1361768A (zh) 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP2129660A2 (en) 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
DK2142516T3 (da) 2007-03-30 2013-04-15 Sanofi Sa Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
TW201010997A (en) * 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
CA2725481A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
RU2496778C2 (ru) 2009-03-09 2013-10-27 Тайхо Фармасьютикал Ко., Лтд. Пиперазиновое соединение, ингибирующее простагландин-d-синтазу
JP2011042643A (ja) 2009-07-24 2011-03-03 Bayer Cropscience Ag 殺虫性カルボキサミド類
JPWO2011043359A1 (ja) 2009-10-06 2013-03-04 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
CN107875155A (zh) 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
EP2527340B1 (en) * 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a pgds inhibitory effect
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
US9290453B2 (en) * 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9187474B2 (en) 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
MX363388B (es) 2012-07-27 2019-03-20 Biogen Ma Inc Agentes moduladores de autotaxina.
EA027809B1 (ru) 2012-07-27 2017-09-29 Биоген Айдек Ма Инк. Соединения, которые являются s1p-модулирующими агентами и/или atx-модулирующими агентами
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
RU2685234C1 (ru) 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
CA2974784A1 (en) 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
CN108430992A (zh) * 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
US10898469B2 (en) * 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
CA3085293A1 (en) * 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds

Also Published As

Publication number Publication date
EP3638672A1 (en) 2020-04-22
US20200123152A1 (en) 2020-04-23
JP2020523367A (ja) 2020-08-06
US11149035B2 (en) 2021-10-19
CN110753692A (zh) 2020-02-04
UY37764A (es) 2019-01-02
TW201908311A (zh) 2019-03-01
BR112019026452A2 (pt) 2020-07-14
WO2018229629A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
JP7675777B2 (ja) 免疫調節剤としての複素環式化合物
CA3066979A1 (en) Chemical compounds as h-pgds inhibitors
JP7303108B2 (ja) 免疫調節剤としての二環式複素芳香環化合物
RU2545023C2 (ru) Трициклические соединения, содержащая их фармацевтическая композиция и их применение для лечения иммунологических и онкологических состояний
JP6199991B2 (ja) ３置換ピラゾール及びｄｌｋ阻害剤としての使用
CA3224732A1 (en) Compounds for targeting degradation of irak4 proteins
ES2987439T3 (es) Compuestos y composiciones para inducir la condrogénesis
WO2022266258A1 (en) Compounds and methods for the targeted degradation of irak-4
KR20210018282A (ko) PD-L1 면역조절제로서의 테트라하이드로-이미다조[4,5-c]피리딘 유도체
JP2020504737A (ja) 免疫調節剤としての複素環式化合物
KR102794907B1 (ko) Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
WO2024023266A1 (en) Novel compounds
TWI762534B (zh) 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物
WO2017046737A1 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
US20210139507A1 (en) Fused pyridines which act as inhibitors of h pgds
JP2022505707A (ja) 置換インドールおよびインダゾール化合物
EP3258929B1 (en) Factor ixa inhibitors
CA3117943A1 (en) Chemical compounds
JP2022532145A (ja) 置換ベンズイミダゾロン化合物
KR102563829B1 (ko) 거대고리 rip2 키나아제 억제제
IL324450A (en) Gsk3a inhibitors and methods of use thereof
OA17143A (en) Diacylglycerol acyltransferase 2 inhibitors
HK1209114B (en) 3-substituted pyrazoles and use as dlk inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231213